Latest filing published 24 Jul 2026 for Angiodynamics INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Chad Thomas Campbell in Angiodynamics Inc, where the filings describe the role as chief executive. Over a trading history stretching from 14 July 2021 to 22 July 2026, the count stands at 28 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The newest entry dates from 24 July 2026: an option exercise, in Angiodynamics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 28 declarations